Philippe Camus, M.D.

Dijon, France

Back to drug

The Drug-Induced Respiratory Disease Website

V.a

Myocarditis (can be fulminate/fulminant)

Can be fatal (PMID 31020225, 31022941). May cause pulmonary edema (PMID 31020225). associate with skeletal muscle inflammation (myositis; PMID 30790071)

Publications

Gürdo?an M, Yalta K, Gürlertop Y, Karahan F, Bulburu ?B, Koçyi?it B, Ustaba??o?lu FE, Çiçin ?

Coexistence of Anti-PD1-Induced Immune Myocarditis and Complete Atrioventricular Block: A Case Report.

The American journal of cardiology 2023 Sep 16;207;35-38 — 2023 Sep 16 — 35-38

Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M, Russo A, Coscioni E, Rossi F, Alfano R, Capuano A

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.

Drug safety 2021 Jun 18;; — 2021 Jun 18

Liu SY, Huang WC, Yeh HI, Ko CC, Shieh HR, Hung CL, Chen TY, Chen YJ

Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation.

Cancers 2019 Apr 24;11; — 2019 Apr 24

Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

The Lancet. Oncology 2018 12;19;1579-1589 — 2018 12 — 1579-1589

Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, Mukherjee SD, Nair V, Leong DP

Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.

The Canadian journal of cardiology 2018 08;34;1059-1068 — 2018 08 — 1059-1068

Yamaguchi S, Morimoto R, Okumura T, Yamashita Y, Haga T, Kuwayama T, Yokoi T, Hiraiwa H, Kondo T, Sugiura Y, Watanabe N, Kano N, Kohno K, Fukaya K, Sawamura A, Yokota K, Ishii H, Nakaguro M, Akiyama M, Murohara T

Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.

The Canadian journal of cardiology 2018 06;34;812.e1-812.e3 — 2018 06 — 812.e1-812.e3

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Journal of the American College of Cardiology 2018 Apr 24;71;1755-1764 — 2018 Apr 24 — 1755-1764

Ederhy S, Cautela J, Ancedy Y, Escudier M, Thuny F, Cohen A

Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors.

JACC. Cardiovascular imaging 2018 Aug;11;1187-1190 — 2018 Aug — 1187-1190

Inayat F, Masab M, Gupta S, Ullah W

New drugs and new toxicities: pembrolizumab-induced myocarditis.

BMJ case reports 2018 Jan 23;2018; — 2018 Jan 23

Frigeri M, Meyer P, Banfi C, Giraud R, Hachulla AL, Spoerl D, Friedlaender A, Pugliesi-Rinaldi A, Dietrich PY

Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists.

The Canadian journal of cardiology 2018 01;34;92.e1-92.e3 — 2018 01 — 92.e1-92.e3

Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM

Smoldering myocarditis following immune checkpoint blockade.

Journal for immunotherapy of cancer 2017 11 21;5;91 — 2017 11 21 — 91

Cheng F, Loscalzo J

Autoimmune Cardiotoxicity of Cancer Immunotherapy.

Trends in immunology 2017 02;38;77-78 — 2017 02 — 77-78

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Rod

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

The New England journal of medicine 2016 Nov 03;375;1749-1755 — 2016 Nov 03 — 1749-1755